Vareniclina 0.5 mg bid n=129
Vareniclina 1 mg bid n=821
Placebo n=805
N谩usea
16%
30%
10%
Insomnio
19%
18%
13%
Sue帽os anormales
9%
13%
5%
Constripaci贸n
5%
8%
3%
Flatulencia
9%
6%
3%
V贸mito
1%
5%
2% -Gonzales D JAMA. 2006; 296(1): 47-55. - Jorenby D JAMA 2006; 296:56
2
3
4
5
6
RR=2,06 180
9 8 7 6 5 4 3 2 1 0
No Fumadores
ExFumadores
1-14
15
Fumadores Cigarrillos/Día
Eventos por 10.000 pessoas-ano
Riesgo Relativo(95% CI)
p<.001
10
161,2
160
140 120
116,6
RR=2,04
100
78,4
80
49
60 40
24
29,2
20 0 Não
Nunca
Sim
Ex-fumante
Fumante atual
-Miller et al. Am J Public Health. 2000;90:768-773.
7
QuarterWatchT: 2010 (Quarter 3)
8
9
10
18 Apr 2012
11
12
13
14
Publicaci贸n Julio 2011
15
16
Publicaci贸n Julio 2011
17
18
[7-22-2011] Chantix may be associated with a small, increased risk of certain cardiovascular adverse events in these patients窶認DA communicated about this potential risk and labeling update in the June 16, 2011 Drug Safety Communication. The absolute risk of cardiovascular adverse events with Chantix, in relation to its efficacy, is small. 19
20
Christine E. Kistler, M.D., M.A.Sc. & Adam O. Goldstein, M.D., M.P.H.
21
Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis J Prochaska , J Hilton BMJ 2012;344:e2856 /4 May 2012
22
Publicaci贸n Julio 2011
23